A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Sponsor: GlaxoSmithKline
This PHASE4 trial investigates Pulmonary Disease, Chronic Obstructive and is currently completed. GlaxoSmithKline leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Feb 2017 — Jul 2017 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Balassagyarmat, Hungary , Bamberg, Germany , Barcelona, Spain , Barnaul, Russia , Brasov, Romania , Brinkum/Stuhr, Germany , Bucharest, Romania , Budapest, Hungary , Chelyabinsk, Russia , Chita, Russia and 61 more locations